£6.90m
+32%vs Jun 2024Active09400979Private limited companyLondon
LDN PHARMA LIMITED
Significant control: Paul Joseph Sweeney (25–50%), Ian Thompson (25–50%)
From public filings as at 31 Aug 2026; may contain errors or be out of date. Verify at Companies House · Terms
Watch this company
Get an email when Companies House records a change for Ldn Pharma Limited: status, filings, accounts, officers or owners. Free.
Not live yet: alerts start by 15 December 2026. We store your email and this company number only, for these alerts. If alerts don’t launch, we tell you and delete your address. Privacy
Coming soon · product and service lists
What does Ldn Pharma Limited sell?
Registered activity: Manufacture of basic pharmaceutical products (SIC 21100). We’re building product and service lists for UK companies. Get this one when it’s ready.
One email, only about this. If we don’t launch within 60 days we’ll tell you. Privacy
01
Summary
LDN PHARMA LIMITED is an active private limited company (company number 09400979) incorporated on 22 January 2015, registered in London. Its registered activity is manufacture of basic pharmaceutical products (SIC 21100). Latest abridged accounts cover the period ending 30 June 2025, showing net assets of £6.90m and cash of £1.07m, with 0 employees on average. As abridged accounts, no profit and loss account is filed, so turnover and profit are not public. Net assets rose 32% on the prior period (£5.24m).
Peer position · net assets
By net assets it sits in the top quarter of 143 comparable companies in London (median £100, upper quartile £10k).
02
Ownership and control
- Mr Paul Joseph Sweeney
- owns 25–50% of shares
- Mr Ian Thompson
- owns 25–50% of shares
Persons with significant control hold 25% or more of shares or voting rights. Smaller shareholdings are only listed in confirmation-statement documents. Directors and secretaries: see the officers list at Companies House.
03
Key dates
- Incorporated
- 22 January 201511 yrs ago
- Next accounts due
- 30 March 2027in 157 days
- Confirmation statement due
- 5 February 2027in 104 days
Due dates are expected from Companies House filing rules; confirm on the official register before relying on them.
04
Activity
- SIC 21100
- Manufacture of basic pharmaceutical products
- SIC 86900
- Other human health activities
- Accounts type
- Unaudited Abridged
- Size band
- MicroCompanies Act thresholds
05
Financials
£1.07m
+144857%vs Jun 2024Not disclosed
0
vs Jun 2024| Period end | Net assets | Cash | Debtors | Creditors <1y | Turnover | Profit | Employees |
|---|---|---|---|---|---|---|---|
| 30 June 2025 | £6.90m | £1.07m | £7,513 | £250k | — | — | 0 |
| 30 June 2024 | £5.24m | £741 | £66k | £367k | — | — | 0 |
Current ratio4.32Current assets ÷ creditors within one year
Figures as filed in iXBRL accounts at Companies House. "—" means the line was not reported in that filing.
06
Filing and accounts signals
- Net assets above zeroNet assets £6,896,503 at 30 June 2025
- Net assets up 10% or more on the prior period+31.6% vs prior period
- Current assets at least 1.5× creditors within one yearCurrent ratio 4.32
- Cash at bank of £50,000 or moreCash £1,074,131
- Incorporated five or more years agoIncorporated 22 January 2015
Neutral facts read from the register and filed accounts, each with its evidence. They are not a rating, a prediction or advice, and may be incomplete or out of date. How each signal is derived.
07
Timeline
- Next accounts duein 157 days
- Confirmation statement duein 104 days
- Accounts period endNet assets £6.90m · abridged accounts
- Accounts period endNet assets £5.24m · abridged accounts
- Incorporated
08
Similar companies in London
09
Reminders for LDN PHARMA LIMITED
Get an email before each filing deadline — accounts and confirmation statement — so nothing is late.